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Abstract
Severity and frequency of gastroesophageal reflux disease (GERD) related symptoms are associated
with impaired health-related quality of life (HRQL). This study evaluated the association between
baseline heartburn severity and endpoint HRQL of patients treated for heartburn and the
relationship between complete resolution of heartburn symptoms and HRQL outcomes after
controlling for baseline severity. We completed a secondary analysis of clinical symptom and HRQL
data from three clinical trials in adult patients receiving either omeprazole or ranitidine treatment
for GERD. HRQL was assessed using the Psychological General Well-Being Index (PGWB) in each
of the three clinical trials, and two of the trials also included the Medical Outcomes Study Sleep
disturbance scale. Gastrointestinal symptoms were evaluated using either the Gastrointestinal
Symptom Rating Scale or a modified version of the scale. Baseline heartburn severity (none/minor,
mild, moderate or severe) was defined based on patient-reported symptoms. Analysis of
covariance (ANCOVA) models were used to compare mean HRQL scores by baseline level of
heartburn symptom severity and whether or not patients experienced complete heartburn
resolution. At baseline, PGWB scores were significantly worse (p < 0.05) for patients with more
severe heartburn symptoms. There were no statistically significant baseline severity by symptom
resolution interactions in any of the ANCOVA models. For all three trials and across all follow-up
assessments, mean PGWB scores were statistically significantly higher for patients with completely
resolved heartburn symptoms versus those whose symptoms were unresolved (all p-values < 0.05).
Few significant effects were observed for sleep disturbance scores. While the severity of heartburn
symptoms at the start of medical treatment for GERD is not associated with improvements in
HRQL in subsequent weeks of treatment, complete resolution of symptoms is associated with
improvements in psychological well-being.
Introduction
Gastroesophageal reflux disease (GERD) is common in
the general population and represents a frequent reason
for visits in primary care practices [1-4]. The spectrum of
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disease manifestations associated with GERD ranges from
mild heartburn to erosive esophagitis and, less com-
monly, may generally include more serious medical con-
ditions such as esophageal ulcer, esophageal stricture, and
a pre-cancerous condition known as Barrett's esophagus
[1]. Effective treatment of GERD is necessary to heal the
esophagus and to provide symptom relief. The frequency
and severity of symptoms associated with GERD have
been demonstrated to diminish patient health-related
quality of life (HRQL) [5-8]. Studies have shown that
medical intervention in the treatment of GERD provides
improvement in GERD-related symptoms and in turn, an
improvement in well-being and functioning (i.e., HRQL)
[5,9-14]. Revicki et al. have demonstrated an association
between the complete resolution of heartburn symptoms
and improvements in measures of HRQL [15]. Few stud-
ies have been published relating the severity of GERD
symptoms at the start of treatment with HRQL outcomes
throughout the course of treatment. Of further interest is
whether complete resolution of heartburn symptoms has
the same effect on patients in terms of HRQL given more
or less severe symptoms at the start of treatment.
The primary objectives of this study were to evaluate the
association between baseline heartburn severity and end-
point HRQL in patients treated for heartburn; and to
examine the relationship between complete resolution of
heartburn symptoms, while controlling for baseline sever-
ity, and HRQL outcomes. Previous research indicates that
baseline severity of disease and health status scores may
be associated with changes in HRQL outcomes [16,17]
where patients with very severe disease (and worse HRQL)
may demonstrate differential impact of effective medical
therapy than those with milder disease. Since the diagno-
sis of GERD and related treatment decisions are based on
severity of symptoms and the reported interference of
GERD symptoms with patient well-being [18], clinicians
treating patients with GERD are concerned about differen-
tial effects of treatment by initial disease severity. It is
therefore useful to evaluate whether the association
between symptom resolution and HRQL varies by base-
line disease severity, since there may be differences in pro-
portion of patients who experience symptom resolution,
depending on pre-treatment disease severity. We per-
formed a secondary analysis of three clinical trials com-
paring omeprazole and ranitidine to evaluate the
relationship between severity of heartburn symptoms at
the start of treatment and HRQL at subsequent weeks of
treatment. A secondary objective was to evaluate whether
complete resolution of heartburn symptoms, while con-
trolling for baseline severity, results in improved well-
being and functioning. The latter objective extends previ-
ous work that demonstrated complete resolution of these
symptoms improves HRQL [15].
Methods
Data sources
Data from three clinical trials were used to evaluate the
relationship between baseline level of heartburn symp-
tom severity and HRQL. Each of the three trials was origi-
nally designed to compare the effectiveness of omeprazole
versus ranitidine in the treatment of patients with symp-
toms of GERD.
Clinical Trial 1
This two-phase multi-center trial was designed to compare
omeprazole and ranitidine in the treatment of patients
with at least moderate to severe heartburn symptoms and
to evaluate HRQL in patients with poorly responsive
symptomatic GERD [5,13]. Phase 1 (open label) enrolled
533 patients with a 6 month or longer history of heart-
burn, including moderate to severe heartburn during four
out of the last 7 days prior to the start of the phase.
Patients enrolled in the open label phase were started on
ranitidine 150 mg twice daily for 6 weeks. Patients who
experienced one or more episodes of moderate to severe
heartburn during Week 6 and who had taken at least nine
ranitidine tablets during Week 6 were classified as non-
responsive. These patients were eligible for Phase 2 (dou-
ble-blind) and were randomized to receive either omepra-
zole 20 mg once daily or ranitidine 150 mg twice daily for
8 weeks. Three hundred sixteen patients (59%) were ran-
domized in the double blind phase of the trial; baseline
and 8-week data were included in this secondary analysis.
Clinical Trial 2
The second study was a multi-center, double-blind, rand-
omized clinical trial designed to compare omeprazole and
ranitidine in the treatment of heartburn and included
baseline and follow-up data (weeks 4, 8, 12, and 16) [14].
Eligible subjects were drawn from four large managed care
health plans and were under the care of a primary care
physician. To be enrolled, patients had to be at least 18
years of age, have heartburn, and have their physician
consider them appropriate candidates for treatment of
suspected GERD. Heartburn was defined as a rising,
uncomfortable burning feeling in the chest behind the
breastbone. Patients were randomly assigned to receive
either omeprazole 20 mg once daily or ranitidine 150 mg
twice daily. Six hundred eighty-five patients were enrolled
in this study.
Clinical Trial 3
This clinical trial was a prospective, multi-center, open-
label, randomized trial designed to evaluate the effective-
ness of omeprazole versus ranitidine in the initial treat-
ment of patients with GERD [8,19]. Patients were enrolled
over a 24-month period from five family practice clinics in
the Charleston, West Virginia area. All enrolled patients
were at least 18 years of age, were clinically diagnosed asHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
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having GERD, and were determined to need pharmaceu-
tical intervention in the treatment of GERD based on fre-
quency of heartburn / acid regurgitation. Patients were
randomly assigned to receive either omeprazole 20 mg
once daily or ranitidine 150 mg twice daily. This study
population had a higher level of chronic illness than the
other two study populations with 61% of the patients
reporting one or more medical co-morbidities. Secondary
analyses included data collected at baseline, 4-, 12-, and
24-week follow-up from 251 patients.
Health-Related Quality of Life Measures
The Psychological General Well-Being Index (PGWB) was
used to evaluate health-related quality of life in each of
the three clinical trials. The Medical Outcomes Study
(MOS) Sleep Disturbance scale was also included in Clin-
ical Trial 1 and Clinical Trial 3.
The PGWB measures psychological well-being and dis-
tress [20,21]. The instrument is composed of 22-items
which, when scored, constitute 6 subscales and one total
score with higher scores indicating better health status
and psychological well-being. Subscale scores include
anxiety, depression, self control, positive well-being, gen-
eral health, and vitality. Normal values for the total score
are considered to fall in the range of 100–105, with
women generally reporting lower well-being than men
[6]. The PGWB has good evidence supporting internal
consistency, test-retest reliability and validity, and has
been shown to be sensitive to gastrointestinal disease
occurrences [6,7,9,13,21-23]. For the purposes of this
study only the PGWB total score was examined.
The MOS Sleep Disturbance scale [24], included in Clini-
cal Trials 1 and 3, is composed of four items pertaining to
sleep initiation and maintenance. The sleep scale ranges
from 0 to 100 with higher scores indicating better sleep
quality (i.e., less sleep disturbance). The MOS Sleep Dis-
turbance score has been evaluated and demonstrates good
reliability and validity [24].
Clinical Measures
To evaluate the gastrointestinal symptoms of patients,
Clinical Trial 1 used both diary cards and the Gastrointes-
tinal Symptom Rating Scale (GSRS). Diary cards were
completed by patients each day for a 1-week period prior
to both the baseline and the 8-week HRQL assessment
[13]. Ninety-seven percent of patients provided complete
diary data during the study. The GSRS is a 15-item, disease
specific instrument used to evaluate common gastrointes-
tinal symptoms [23,25]. The items are measured on a 7-
point Likert-type scale ranging from 1 = 'no discomfort' to
7 = 'very severe discomfort'. The GSRS was administered at
baseline and 8-week follow-up. To assess the gastrointes-
tinal symptoms in Clinical Trial 2, patients were asked
about how much of the time during the past 7 days they
were bothered by each of three symptoms: heartburn,
regurgitation, and difficulty swallowing. These three ques-
tions were asked at baseline and follow-up weeks 4, 8, 12,
and 16 and were measured on a 6-point response scale:
from 1 = 'none of the time' to 6 = 'all of the time' [14].
Clinical Trial 3 used the GSRS to assess gastrointestinal
symptoms of patients at baseline and follow-up weeks 4,
12, and 24.
Baseline Heartburn Severity
Baseline heartburn severity (i.e., none/minor, mild, mod-
erate, severe) was defined based on their level of heart-
burn symptoms. For Clinical Trial 1 and Clinical Trial 3
baseline severity was determined using the GSRS heart-
burn item: Have you been bothered by HEARTBURN during
the past week? (by heartburn we mean a burning pain or dis-
comfort behind the breastbone in your chest). For Clinical
Trial 2 severity was determined based on the patients'
indicated frequency (i.e., 'none of the time' to 'all of the
time') of bothersome heartburn during the 7 days prior to
baseline assessment.
Complete Symptom Resolution
For Clinical Trial 1 diary data were used to define whether
or not patients were experiencing complete resolution of
heartburn symptoms. Using these data, complete resolu-
tion of heartburn symptoms was defined for persons who
specified no episodes of heartburn during the 7 days prior
to the follow-up visit [15]. For Clinical Trial 2, patients
indicating that they were bothered by heartburn 'none of
the time' during the 7 days prior to the follow-up visit
were classified as completely resolved [15]. For Clinical
Trial 3, completely resolved patients were identified using
the GSRS heartburn item. Complete resolution status was
determined at each follow-up period across each of the
three studies [15].
Statistical Analyses
PGWB total and MOS Sleep Disturbance scores were com-
pared between patients classified as having none/minor,
mild, moderate, or severe heartburn symptoms at start of
treatment. Comparisons were conducted for each of the
three clinical trials and were performed independent of
treatment group assignment. To evaluate whether base-
line heartburn severity is associated with endpoint HRQL
scores, we focused on the interaction between baseline
symptom severity and complete resolution status at fol-
low-up, based on an analysis of covariance (ANCOVA)
model. This ANCOVA model included the interaction
term and main effects for baseline symptom severity and
complete resolution. The covariates included in the mod-
els were age, gender, relevant baseline HRQL measure. A
separate ANCOVA model was fit for each follow-up
assessment for each of the three trials. Patients withHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
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missing data for any of the variables included in the mod-
els were dropped from the analyses. A second set of
ANCOVAs evaluated mean PGWB total scores and Sleep
Disturbance scores by symptom resolution status, con-
trolling for baseline symptom severity, age, gender and
baseline score. Standard errors (SE) for the covariate
adjusted follow-up scores are reported. All statistical tests
were two-sided with p-values ≥ 0.05 considered to be sta-
tistically significant. Analyses were performed using SAS
System Software Package, Version 8.0.
Results
Baseline Characteristics
Patient demographic data and baseline HRQL measures
are presented in Table 1. The age distribution of patients
was similar across the three trials. The mean age ranged
from 45.1 years (SD = 13.0) (Clinical Trial 1) to 47.9 (SD
= 14.1) (Clinical Trial 2). The proportion of male patients
enrolled in each trial ranged from 38% to 43%. The pro-
portion of Caucasian subjects ranged from 69% to 91%
and was less in Clinical Trial 2 compared with the other
studies.
The proportion of patients classified as having moderate
or severe heartburn symptoms at baseline was substan-
tially greater for Clinical Trial 3 (75%) compared to Clin-
ical Trials 1 (24%) and 2 (29%). The defined level of
symptom severity is reflective of the heartburn items used
to classify the patients. For example, patients in Clinical
Trial 3, when responding to "Have you been bothered by
HEARTBURN during the past week?" had an average
response of 4.5 (on a 7-point scale) compared to 3.1
(based on the same 7-point scale) and 3.9 (6-point scale)
for Clinical Trial 1 and Clinical Trial 2, respectively. Base-
line HRQL measures were also lower for Clinical Trial 3
reflecting greater impairment at baseline (Table 1).
Relationship Between Baseline Heartburn Severity and 
HRQL
Table 2 presents mean baseline HRQL measures by base-
line severity of heartburn symptoms. Patients experienc-
ing more severe heartburn symptoms reported lower
(more impaired) PGWB scores in all three studies (p <
0.05) and more sleep disturbance in clinical trials 1 and 3
(p < 0.05). For example, patients from Clinical Trial 1 who
were classified as having no or minor heartburn symp-
toms at baseline had a mean baseline Sleep Disturbance
score of 74.1 (s.e. = 3.0) while patients classified as having
severe heartburn symptoms had a mean baseline Sleep
Disturbance score of 36.4 (s.e. = 6.7) (p < 0.0001). This
indicates that patients with more severe heartburn symp-
toms also report more problems with their sleep.
Relationship Between Baseline Severity, Symptom 
Resolution Status, and Endpoint HRQL Outcomes
The ANCOVA models were run using endpoint PGWB
total or Sleep Disturbance scores as the dependent varia-
ble and including factors for baseline symptom severity
and complete resolution status, with adjustment for age,
gender and baseline score. The interaction effect of base-
line severity of heartburn symptoms and heartburn reso-
lution status was statistically significant in only one of
twelve ANCOVA models. Because of very small sample
Table 1: Patient demographics and baseline HRQL.
Clinical Trial 1 Clinical Trial 2 Clinical Trial 3
N 316 685 251
Male% 43% 38% 39%
Caucasian% 89% 69% 91%
Age, mean (s.d.) 45.5 (13.0) 47.9 (14.1) 45.1 (14.1)
Omeprazole% 49% 50% 52%
Heartburn Severity%1
None/Minor 21% 37% 17%
Mild 53% 34% 8%
Moderate 20% 24% 36%
Severe 4% 5% 39%
Missing 2% 0% 0%
Heartburn-related symtoms2 3.1 (0.8) 3.9 (1.0) 4.5 (1.8)
PGWB Total, mean (s.d.) 76.3 (16.4) 73.0 (18.2) 58.0 (21.8)
MOS Sleep, mean (s.d.) 67.7 (25.7) NA 55.5 (29.2)
1Based on the diary data, all patients randomized in Phase 2 of Clinical Trial 1 had at least one episode of moderate to severe heartburn (Phase 2 
enrollment criteria). Patient responses to the GSRS heartburn item varied compared to the diary data. Hence, a proportion of the population is 
indicated as having heartburn (during the week previous to the baseline assessment) that was of less than moderate discomfort. 2GSRS heartburn 
item (1–7) scale for Clinical Trials 1 and 3 and heartburn item (1–6 scale) for Clinical Trial 2.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
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Table 2: Baseline HRQL by baseline measure of heartburn severity
Baseline level of 
heartburn severity
Clinical Trial 1 Clinical Trial 2 Clinical Trial 3








nP G W B  T o t a l ,  
mean (s.e.)
MOS Sleep, mean 
(s.e.)
None/Minor 65 81.0 (1.9) * 74.1 (3.0) * 250 74.5 (1.1) * NA 43 71.4 (3.1) * 64.1 (4.4) *
Mild 166 77.8 (1.2) 70.3 (1.9) 232 74.9 (1.2) NA 21 63.0 (4.5) 60.8 (6.4)
Moderate 63 71.0 (2.0) 61.3 (3.1) 165 69.6 (1.4) NA 90 58.8 (2.2) 58.0 (3.1)
Severe 13 60.1 (4.3) 36.4 (6.7) 36 66.6 (3.0) NA 97 50.1 (2.1) 48.2 (2.9)
1Due to missing data points Ns may not sum to total trial sample size. *p < 0.05 for test of overall differences in means from one-way ANCOVA 
model.
Table 3: Adjusted mean PGWB total scores by baseline severity of heartburn symptoms
Trial/Follow-up n Mean (s.e.)
Clinical Trial 1
8 Weeks None/Minor 59 80.5 (1.6)
Mild 159 80.3 (1.0)
Moderate 59 82.0 (1.6)
Severe 13 87.5 (3.5)
Clinical Trial 2
4 Weeks None/Minor 237 82.4 (0.8)
Mild 219 81.8 (0.9)
Moderate 160 82.5 (1.0)
Severe 33 82.3 (2.2)
8 Weeks None/Minor 234 83.4 (0.9)
Mild 219 82.1 (0.9)
Moderate 155 83.7 (1.1)
Severe 35 82.3 (2.3)
12 Weeks None/Minor 231 84.4 (0.9)
Mild 217 83.1 (1.0)
Moderate 151 85.8 (1.2)
Severe 34 82.5 (2.4)
16 Weeks None/Minor 229 86.0 (0.9)
Mild 211 84.8 (1.0)
Moderate 153 88.4 (1.2)
Severe 32 86.8 (2.5)
Clinical Trial 3
4 Weeks None/Minor 40 76.0 (3.0)
Mild 21 73.7 (3.9)
Moderate 79 72.8 (2.0)
Severe 84 70.9 (2.0)
12 Weeks None/Minor 37 76.9 (3.2) *
Mild 17 71.9 (4.5)
Moderate 71 74.0 (2.3)
Severe 69 64.3 (2.4)
24 Weeks None/Minor 37 74.5 (3.5)
Mild 18 69.6 (4.8)
Moderate 68 72.4 (2.5)
Severe 74 67.4 (2.4)
*p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline PGWB total score, 
and symptom resolution status.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
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sizes for the severe group in this ANCOVA, these findings
may not be meaningful. There was no evidence for signif-
icant interactions between baseline heartburn severity and
complete symptom resolution in any of the models
evaluated.
For Clinical Trials 1 and 2, baseline symptom severity was
not associated with endpoint PGWB total scores. Covari-
ate adjusted mean PGWB total scores by baseline severity
level are presented in Table 3. For example in Clinical
Trial 2, severity of baseline heartburn symptoms was not
statistically significantly associated with PGWB total score
at any follow-up point (Table 3; weeks 4, 8, 12, or 16; all
p > 0.05). In Clinical Trial 3, baseline severity of heartburn
symptoms was a statistically significant factor in the
ANCOVA models for PGWB total score at week 12 (Table
3; p = 0.006). Adjusted mean PGWB total scores at week
12 were higher for patients classified as having none/
minor heartburn symptoms (mean = 76.9; SE = 3.2) and
moderate heartburn symptoms (mean = 74.0; SE = 2.3)
compared to patients classified as having severe heartburn
symptoms (mean = 64.3; SE = 2.4) (p = 0.0025 and p =
0.0031 respectively).
Baseline symptom severity was not statistically signifi-
cantly associated with Sleep Disturbance scores in Clinical
Trial 1 (see Table 4). In Clinical Trial 3, the overall effect
of baseline heartburn severity on week 12 Sleep Distur-
bance scores was statistically significant (p = 0.0471). The
adjusted mean Sleep Disturbance scores were higher for
patients with none/minor heartburn symptoms (men =
75.0; SE = 3.8) and moderate heartburn symptoms (mean
= 71.3; SE = 2.9) compared to those with severe symptoms
(mean = 62.8; SE = 2.9) (p = 0.0113 and p = 0.0315
respectively).
For all three clinical trials, complete heartburn symptom
resolution was associated with improved PGWB total
scores (see Table 5). In Clinical Trial 1, complete heart-
burn symptom resolution was a statistically significant
factor associated with 8-week PGWB total score (p =
0.0329). The adjusted mean PGWB total score at 8-week
follow-up was 84.2 (SE = 1.5) for completely resolved
patients compared to 80.9 (SE = 1.2) for patients not
resolved. In Clinical trial 2, at each follow-up assessment
adjusted mean PGWB total scores were consistently
higher for patients who experienced complete resolution
of heartburn symptoms versus those without heartburn
resolution. For weeks 4, 8, and 12 adjusted mean PGWB
total scores were 3 points higher for patients experiencing
complete resolution of heartburn symptoms compared to
those not resolved (p = 0.0034, p = 0.0105, and p= 0.0098
respectively). At week 16, patients who were completely
resolved had an adjusted mean PGWB total score 7 points
higher than patients who were not resolved (p < 0.0001).
For Clinical Trial 3, resolution status was statistically sig-
nificantly associated with differences in adjusted mean
PGWB total scores at each follow-up period (see Table 5).
The observed difference in adjusted mean PGWB total
scores between completely resolved patients and non-
Table 4: Adjusted mean Sleep Disturbance scores by baseline severity of heartburn symptoms
Trial/Follow-up N Mean (s.e.)
Clinical Trial 1
8 Weeks None/Minor 59 75.0 (2.3)
Mild 158 73.9 (1.5)
Moderate 58 77.3 (2.4)
Severe 13 74.3 (5.1)
Clinical Trial 3
4 Weeks None/Minor 39 75.7 (3.8)
Mild 20 69.2 (5.1)
Moderate 72 72.4 (2.7)
Severe 79 66.4 (2.6)
12 Weeks None/Minor 36 75.0 (3.8) *
Mild 16 70.8 (5.6)
Moderate 66 71.3 (2.9)
Severe 65 62.8 (2.9)
24 Weeks None/Minor 33 75.6 (4.3)
Mild 14 73.3 (6.4)
Moderate 63 70.0 (3.1)
Severe 69 66.3 (3.0)
*p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline sleep disturbance 
score, and symptom resolution status.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
Page 7 of 9
(page number not for citation purposes)
resolved patients at week 4 and week 12 was 8.3 (p =
0.0007) and 8.8 (p = 0.0021) respectively. At Week 24 the
mean adjusted PGWB total score was approximately 15
points higher for resolved patients compared to non-
resolved patients (p < 0.0001).
There were no statistically significant differences observed
by heartburn symptom resolution on mean Sleep Distur-
bance scores in the ANCOVA models (see Table 6).
Discussion
This secondary analysis was designed to evaluate the rela-
tionship between baseline level of heartburn symptom
severity, resolution of heartburn symptoms, and HRQL
outcomes assessed at various time-points during pharma-
ceutical treatment for GERD. This study failed to find
evidence supporting the interaction between baseline
symptom severity and complete resolution of heartburn
symptoms on PGWB total or Sleep Disturbance scores.
However, baseline symptom severity was significantly
associated with psychological well-being, as measured by
Table 5: Adjusted mean PGWB total score by complete heartburn resolution status
Trial/Follow-up Resolution Status n Mean (s.e.)
Clinical Trial 1
8 Weeks Completely resolved 97 84.2 (1.5)*
Not resolved 193 80.9 (1.2)
Clinical Trial 2
4 Weeks Completely resolved 263 83.7 (0.9)*
Not resolved 386 80.8 (0.8)
8 Weeks Completely resolved 257 84.3 (1.0)*
Not resolved 386 81.4 (0.9)
12 Weeks Completely resolved 250 85.5 (1.0)*
Not resolved 383 82.4 (0.9)
16 Weeks Completely resolved 235 90.0 (1.1)*
Not resolved 390 82.9 (0.9)
Clinical Trial 3
4 Weeks Completely resolved 116 77.5 (1.8)*
Not resolved 108 69.2 (1.9)
12 Weeks Completely resolved 73 76.2 (2.3)*
Not resolved 121 67.4 (2.0)
24 Weeks Completely resolved 72 78.6 (2.5)*
Not resolved 125 63.3 (2.1)
*p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline PGWB total score, 
and baseline severity.
Table 6: Adjusted mean Sleep Disturbance scores by complete heartburn resolution status
Trial/Follow-up Resolution Status n Mean (s.e.)
Clinical Trial 1
8 Weeks Completely resolved 97 76.3 (2.1)
Not resolved 191 74.0 (1.7)
Clinical Trial 3
4 Weeks Completely resolved 103 72.4 (2.3)
Not resolved 107 69.5 (2.5)
12 Weeks Completely resolved 116 72.0 (2.9)
Not resolved 67 67.9 (2.4)
24 Weeks Completely resolved 114 74.4 (3.2)
Not resolved 65 68.1 (2.7)
*p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline sleep disturbance 
score, and baseline severity.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
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the PGWB, and sleep problems. Those patients reporting
greater severity in heartburn symptoms were more likely
to report psychological distress and impaired well-being
compared with those who reported no or milder symp-
toms. Heartburn severity was also associated with greater
reports of sleep problems in these GERD patients.
We evaluated the relationship between complete resolu-
tion of heartburn symptoms and PGWB and Sleep Distur-
bance scores, after controlling for baseline levels of
symptom severity. Baseline heartburn severity was signifi-
cant in only one model for the PGWB and one model for
Sleep Disturbance scores, both for Clinical Trial 3 at the
12 week follow-up. For most of the analyses, baseline
symptom severity was not significantly associated with
endpoint health outcomes. In general, complete resolu-
tion of heartburn symptoms resulted in reports of
improved psychological well-being. Those patients
reporting complete relief from their heartburn symptoms
also reported better psychological well-being. The
observed differences in mean PGWB total scores are clini-
cally meaningful, since differences or changes of 4 to 5
points represent the minimally important difference for
the PGWB [22,26]. Using a 4-point difference as the crite-
ria for minimal important, 5 out of the 8 comparisons
(63%) are clinically meaningful. No association between
symptom resolution and Sleep Disturbance scores was
observed in this secondary analysis. These results extend
previously published results that demonstrated complete
resolution of heartburn symptoms is associated with
improved patient functioning and well-being [15]. Even
after adjusting for baseline symptom severity, complete
resolution of heartburn symptoms remains associated
with improved psychological well-being. These findings
were consistent across all three studies.
Other published research has reported an association
between GERD-related gastrointestinal symptoms (e.g.,
heartburn, epigastric pain, regurgitation) and patient
functioning and well-being [5-7,10,23]. An earlier study
has shown that the complete resolution of these symp-
toms results in greater patient functioning and well-being
compared to continued symptoms and to an overall
improvement in functioning and well-being over the
course of medical treatment [15]. While these analyses did
not demonstrate significant differences in HRQL by base-
line severity of heartburn symptoms, they did provide fur-
ther support for the association between complete
resolution of these symptoms and improvement in
HRQL.
Recently published work by Farup, et al. reported that
measures of nocturnal GERD, such as discomfort with
nocturnal GERD symptoms, frustration with sleep loss,
and worry and concern about symptoms were associated
with impaired HRQL [27]. Earlier work by Revicki et al.
demonstrated a negative and statistically significant corre-
lation between both the continuous measures of number
and severity of heartburn episodes and the sleep distur-
bance scores [13]. Others have reported that there are no
statistically significant associations between measures of
symptom severity and the sleep disturbance scores [8].
Analyses presented in this report failed to demonstrate
that baseline severity of heartburn symptoms had an
effect on measures of sleep disturbance during the course
of medical treatment of GERD.
Limitations
Interpretation of the findings of this study should be
moderated by several limitations. One limitation of the
study is that the information used to generate the two pri-
mary study variables (i.e., baseline symptom severity,
complete resolution of symptoms) was collected through
patient self-report and that these self-reported outcomes
were measured differently for each of the three studies.
The patient diary reports used in Clinical Trial 1 collected
information on symptom frequency and severity. Clinical
Trials 2 and 3 collected information on discomfort or fre-
quency of symptoms. Clinician assessments, patient diary
data, and patient self-report data have been observed to be
in general agreement when using the GSRS [23]. The
patient reports of heartburn symptoms are believed to be
reliable and valid.
A second limitation is the means by which the baseline
heartburn severity measure was defined across all three
clinical trials. The severity measure was defined based on
physician consultation following an examination of the
distribution of responses to heartburn symptom items for
each of the three studies. It is uncertain as to the extent
that modifications in this measure would impact the
results. However, examination of mean HRQL scores at
baseline has demonstrated a clear association between
symptom severity and HRQL scores.
In conclusion, this secondary analysis of clinical and
HRQL data from three clinical trials demonstrated that
complete resolution of heartburn symptoms is associated
with improved psychological well-being in patients with
GERD. No significant association was seen between com-
plete resolution of heartburn symptoms and sleep prob-
lems. Adjusting for baseline heartburn severity did not
affect the relationship between symptom resolution and
psychological well-being. In general, the severity of heart-
burn symptoms at the start of medical treatment for
GERD does not modify the association between complete
symptom resolution and follow-up HRQL outcomes.
Complete resolution of heartburn symptoms is associated
with improvements in overall psychological well-being,
but not sleep disturbance outcomes. Medical and surgicalPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/73
Page 9 of 9
(page number not for citation purposes)
treatment of GERD is focused on relief and complete res-
olution of heartburn, and other, symptoms and in
improving patient HRQL. These findings confirm that
relief of GERD-related symptoms is associated with signif-
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